Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
Clinical trial NCT03977584 · COMPLETED
Trial details
- NCT number
- NCT03977584
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-10
- Primary completion
- 2022-04-19
- Enrollment
- 114
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.